Biotech Values

[spartex]

RPRX- Question on 10-K info

On page 9 under "Competition" of RPRX's recent 10-K, for treatment of uterine fibroids and endometriosis is says:

"There are additional companies developing similar progesterone-blocking technology. Asoprisnil, an anti-progestin being developed by TAP Pharmaceuticals in partnership with Schering AG, is currently in Phase III clinical trials."

Question: From previous postings (this one and others) I read that this trial was stopped for Asoprisnil development; is this text within RPRX's 10-K just outdated information?

Thanks for anyones thoughts on this.